Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Sartorius AG    SRT   DE0007165607


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius : closes acquisition of selected assets of Danaher Life...

05/28/2020 | 10:56am EST

Press Release

Göttingen, April 30, 2020

Sartorius closes acquisition of selected assets of Danaher Life Sciences

  • Broadens portfolio for the development and production of biotech medicines
  • Course set for successful integration

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully closed the acquisition of selected life science businesses of Danaher Corporation. The transaction was completed on April 30, 2020, after receiving the required regulatory approvals.

"The acquisition of this portfolio is a further milestone for Sartorius. The assets we purchased are an excellent strategic and operational fit with both our divisions. We are very pleased to welcome approximately 300 new Sartorius employees and to combine our expertise to become even more relevant together for our biopharma and life science customers," said Sartorius Executive Board Chairman and CEO Dr. Joachim Kreuzburg. Sartorius paid a purchase price of 825 million U.S. dollars for the acquisition and, upon execution of the purchase agreement on October 19, 2019, has been preparing for integration of the acquired businesses into the two divisions of the Sartorius Group. Despite the special conditions prevailing during the pandemic crisis, integration can therefore be initiated immediately following the closing.

The businesses acquired by Sartorius generated revenue of approximately 170 million U.S. dollars in 2019 and cover various laboratory and bioprocessing technologies, which are complementary to the portfolio lineups of both Sartorius divisions. The company's broader offering as a result of the acquisition will support customers even more comprehensively in the development of biotech medicines and vaccines, as well as in the safe and efficient production of such pharmaceuticals. Sartorius is thus extending its market position in bioanalytics as well as in key areas of the manufacture of biotech medications.

The FortéBio business for label-free biomolecular characterization includes innovative protein analysis instruments, biosensors and reagents that are used in drug discovery and will be integrated into the Bioanalytics unit within the Sartorius Lab Products & Services Division. The products are based on patented biolayer interferometry technology and perform real-time analysis of various biomolecular interactions. FortéBio employs approximately 200 people worldwide, has production sites in Fremont, California, USA, and Shanghai, China, and accounts for close to half of the revenue generated by the acquired businesses.

With the chromatography systems and resins business also acquired, Sartorius is expanding the portfolio of its Bioprocess Solutions Division in the downstream processing area. This business addresses an essential step in the purification of biopharmaceuticals and encompasses both reusable and single-use equipment, columns and resins. Furthermore selected product groups in the areas of stainless steel hollow fiber and single-use technology tangential flow filtration systems and single-use flow kits will additionally strengthen the division's portfolio lineup in downstream processing. A further asset to be allocated to the Bioprocess Solutions Division is the SoloHill business covering microcarrier technology and particle validation

1 | 2

standards used in cell cultures and other bioprocesses. Together, these various business entities employ approximately 100 people at their sites in Portsmouth, U.K.; Cergy, France; Ann Arbor, Michigan, USA; and Hopkinton, Massachusetts, USA.

Sartorius already provided information on the impact of this transaction on its financial forecast for the current year in its first-quarter earnings release of April 21, 2020. You will find this publication here at https://www.sartorius.com/en/company/newsroom.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.


Petra Kirchhoff

Head of Corporate Communications and Investor Relations +49 (0)551.308.1686 petra.kirchhoff@sartorius.com


Follow Sartorius on Twitter@Sartorius_Group and on LinkedIn.

2 | 2


Sartorius AG published this content on 30 April 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 May 2020 14:55:10 UTC

© Publicnow 2020
All news about SARTORIUS AG
01/15SARTORIUS : Partners With RoosterBio to Advance Cell and Gene Therapy Manufactur..
01/06SARTORIUS : to acquire Novasep's chromatography process equipment...
01/05SARTORIUS STEDIM BIOTECH SA : Full-year report of -3-
01/05SARTORIUS STEDIM BIOTECH SA : Full-year report of -2-
01/04SARTORIUS VORZUEGE : Receives a Buy rating from JP Morgan
01/04SARTORIUS STEDIM BIOTECH SA : Declaration relative to the number of shares and v..
2020SARTORIUS : and Evotec Partner With Start-up Curexsys on IPSC-Based...
2020PRESS RELEASE : Evotec and sartorius partner with -2-
2020SARTORIUS : pays employees a coronavirus bonus
More news
Sales 2020 2 305 M 2 785 M 2 785 M
Net income 2020 233 M 282 M 282 M
Net Debt 2020 1 759 M 2 125 M 2 125 M
P/E ratio 2020 114x
Yield 2020 0,23%
Capitalization 24 626 M 29 774 M 29 754 M
EV / Sales 2020 11,4x
EV / Sales 2021 9,60x
Nbr of Employees 10 008
Free-Float 46,8%
Duration : Period :
Sartorius AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 246,58 €
Last Close Price 345,00 €
Spread / Highest target 1,74%
Spread / Average Target -28,5%
Spread / Lowest Target -80,1%
EPS Revisions
Managers and Directors
Joachim Kreuzburg Chief Executive Officer
Lothar Kappich Chairman-Supervisory Board
Volker Niebel Head-Production, Procurement & Business Operations
Rainer Lehmann Chief Financial Officer
Oscar-Werner Reif Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS AG0.00%29 774